SAN DIEGO, Jan. 27, 2011 /PRNewswire/ -- Profil™ Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today that CEO Dr. Marcus Hompesch is an invited speaker at the Ramanbhai Foundation 5th International Symposium and ISCR's 4th Annual Clinical Research Conference in February.
The Ramanbhai Foundation's International Symposium will be held February 1-4 in Ahmedabad, India and is hosted by the Zydus Research Center, the research arm of Indian pharmaceutical company Zydus Cadila. The symposium's speakers include world-leading scientists from academia and the pharmaceutical industry specializing in drug research and development for cancer, inflammation, and cardio-metabolic diseases. Profil Institute's Dr. Hompesch will speak on the topic of selecting the appropriate target populations for early phase clinical research and first in human studies of diabetes drugs.
Dr. Hompesch will also present at the Indian Society for Clinical Research's (ISCR) 4th Annual Clinical Research Conference held February 11-12 at the Crowne Plaza Hotel in Gurgaon, India. The conference's focus is strengthening India's domestic clinical research industry through best practices, stricter regulatory standards and global partnerships. Dr. Hompesch will present on the topic of early clinical development in India and its proof of concept in diabetes.
"Historically India's pharmaceutical companies have focused on providing outsourcing and on competitive manufacturing of generics, APIs, and chemicals used in the manufacturing of drugs," said Dr. Marcus Hompesch, Profil Institute CEO. "However, healthcare has become a key priority for the Indian government, and we are now seeing a paradigm shift as India strives to bolster its position in the pharmaceutical and clinical research industry as a global partner, innovator and competitor."
India's private sector is eager for outside partnerships. Profil Institute has become an advisor to Indian companies building the capabilities and establishing stricter standards to perform clinical trials, and, in what is a turn of traditional roles, Profil is seeing Indian companies begin to outsource early phase clinical trials in diabetes to Profil Institute in the US.
Dr. Hompesch continued, "Diabetes is a rapidly growing chronic disease in India. According to a recent analysis by PricewaterhouseCoopers titled Pharma 2020, it is estimated that the number of Indians with diabetes is projected to reach 73.5 million in 2025 and the number of clinical trials in general in India are expected to grow 25-30 percent annually. India's needs and participation in the global pharmaceutical industry must not be ignored."
More information about Dr. Hompesch's presentations at these and other conferences is available on Profil Institute's website at www.profilinstitute.com/News/ResearchNews.
About Profil™ Institute for Clinical Research, Inc.
Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research. The company's advances in early phase drug research and its specific focus on diabetes, obesity and cardio-metabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.
To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 140 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices. The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Düsseldorf, Columbia University, University of Michigan and Harvard University.
For more information visit www.profilinstitute.com.
|SOURCE Profil Institute for Clinical Research, Inc.|
Copyright©2010 PR Newswire.
All rights reserved